MAb51-31-ADC / MedAbome - LARVOL DELTA

Preclinical efficacy of a first-in-class anti-Integrin α/β ADC in hard-to-treat solid tumors (AACR 2026) - "MAb51-31-ADC is a promising therapeutic candidate for treating solid tumors, with selective recognition of a tumor-specific ITGα/β epitope potentially enabling strong antitumor efficacy and reduced off-target effects. Ongoing studies include evaluation of MAb51-31-ADC in patient-derived xenograft (PDX) models of gastrointestinal (GI) cancers, as well as retrospective analyses of target expression in tumor samples, to further support its clinical development."

ADC • Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer